Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10543265 | 0.91 | S1PR4 (0.56) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL401811 | 0.87 | CSNK2A1 (0.51) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL4827025 | 0.87 | MAPT (0.50) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL13125206 | 0.87 | MAPT (0.53) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL19816401 | 0.85 | MAPT (0.52) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL4841594 | 0.85 | MAPT (0.49) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL14930507 | 0.85 | THRA (0.56) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL14926450 | 0.84 | THRA (0.62) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL4841582 | 0.84 | MAPT (0.48) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL5152503 | 0.84 | KDM4E (0.50) | MAPTMEN1KMT2ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293790-A1 | SUBSTITUTED ARYL OXIMES | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-7420083-B2 | Substituted aryloximes | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1667676-A1 | 4-(1-BENZOFURAN-3-YL-METHYLIDENEAMINOXY-PROPOXY)-BENZOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS | Wyeth (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1663189-A1 | 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY)-PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS | Wyeth (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050215626-A1 | Substituted benzofuran oximes; inhibiting PAI-1 activity; Plasminogen Activator Inhibitor (PAI); treating thrombosis, pulmonary fibrosis, stroke, myocardial ischemia, cardiovascular disease, chronic obstructive pulmonary disease, diabetes, Alzheimer's disease, renal fibrosis, or cancer | WYETH (US) | 2005-09-29 | — | — | US | disclosed |
| WO-2005030193-A1 | 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY) -PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBOSIS | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030199-A1 | 4-(1-BENZOFURAN-3-YL-METHYLIDENEAMINOXY.PROPOXY))-BENZOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBOSIS | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070584-A1 | Substituted aryloximes | WYETH (US) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070584-A1 | Substituted aryloximes | AHR, NQO1, AOX1 | MAPT 4769/4885MEN1 4290/4885KMT2A 416/4885 |
| US-20050215626-A1 | Substituted benzofuran oximes; inhibiting PAI-1 activity; Plasminogen Activator Inhibitor (PAI); treating thrombosis, pulmonary fibrosis, stroke, myocardial ischemia, cardiovascular disease, chronic obstructive pulmonary disease, diabetes, Alzheimer's disease, renal fibrosis, or cancer | SERPINE1, PLAT, SERPINB1 | MAPT 930/4885MEN1 1688/4885KMT2A 3409/4885 |
| US-20080293790-A1 | SUBSTITUTED ARYL OXIMES | HCCS, AOX1, TET2 | MAPT 4362/4885MEN1 4006/4885KMT2A 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.